Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NEPH - Nephros Inc


Previous close
1.83
0   0%

Share volume: 1,584
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST

PREVIOUS CLOSE
CHG
CHG%

$1.83
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
-0.54%
1 Month
-16.82%
3 Months
-16.82%
6 Months
-40.97%
1 Year
10.13%
2 Year
31.65%
Key data
Stock price
$1.83
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.35 - $4.04
52 WEEK CHANGE
$0.13
MARKET CAP 
19.296 M
YIELD 
N/A
SHARES OUTSTANDING 
10.544 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,299
AVERAGE 30 VOLUME 
$15,458
Company detail
CEO:
Region: US
Website: nephros.com
Employees: 56
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil

Recent news